The firm served as lead counsel on behalf of Oklahoma Medical Research Foundation in a patent infringement suit brought in the Northern District of Oklahoma against Alexion Pharmaceuticals. The patents related to complement-inhibition technology and their use in a drug marketed by Alexion to treat a rare, debilitating and life-threatening disease. After replacing OMRF’s previous counsel in the matter and soon after claim construction briefing was complete, we obtained a settlement. It included payment to our client as well as public acknowledgement that individuals affiliated with OMRF were the true inventors of the technology at issue.

Oklahoma Med. Research Found. v. Alexion Pharmaceuticals, Inc., No. 07-163 (N.D. Okla. filed Mar. 15, 2007).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Review of gaming licenses for an online gaming company
Represented a major online gaming company in connection with review of current gaming licenses in various jurisdictions with respect to a provision more
Patterson v. Nestlé Waters, et al.
Represented Nestlé Waters North America Inc. in a lawsuit brought in California by one of its production workers alleging that she was discriminated more
Asbestos property damage litigation for a national building and construction products manufacturer
Served as defense counsel for a national building and construction products manufacturer in landmark asbestos property damage litigation. more
Settlement of a major title insurance claim for a 54 acre development project
Served as lead counsel representing the developer of a high profile, 54 acre project in a major title insurance claim arising out of an easement more